Efficacy and Safety of Intranasal Fentanyl in the Treatment of Breakthrough Pain (FT-018-IM)
Status:
Completed
Trial end date:
2008-03-01
Target enrollment:
Participant gender:
Summary
Primary objectives:
- To confirm the efficacy of intranasal fentanyl titrated to doses 50, 100 or 200 µg for
treatment of breakthrough pain (BTP) in cancer patients
- To establish long-term safety of treatment with intranasal fentanyl
Secondary objectives:
- To explore the relationship between dose of background opioid treatment and titrated
fentanyl dose